These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2004-002176-42 Open randomized study to evaluate the efficacy of i.v. iron support (ferrum gluconate, 125 mg i.v. infusion weekly for 6 weeks) in primary solid tumour patients (breast, lung, colon-rectum and gynecol... bad-data
Reported results 2005-001300-39 A phase 2, multi-centre, randomized, double-blind, placebo-controlled, parallel-group 3 arms pilot study to assess the efficacy, the safety and the pharmacokinetics of two treatment schedules of rep... 2008-06-19 due-trials
Reported results 2010-019424-31 A phase 2 multicenter, randomized, open label, parallel assignment, pilot study to assess the efficacy and safety of reparixin following a single infusion islet transplantation in patients with type... 2013-04-30 due-trials
Reported results Terminated 2011-000756-42 A phase 2, multicentre, single arm, pilot study to assess the efficacy and the safety of 150 mg twice a day oral DF2156A in patients with active bullous pemphigoid. Pilotstudie der Phase 2, multize... 2012-07-11 due-trials
Reported results 2011-006201-10 A phase 3, multicenter, randomized, double-blind, parallel assignment study to assess the efficacy and safety of reparixin in pancreatic islet transplantation 2016-12-09 due-trials
Exempt, with results 2012-002527-15 Study Brand Name : REPARO Study full title: An 8-week phase I/II, multicenter, randomized, double-masked, vehicle controlled parallel group study with a 48 or 56 week follow-up period to evaluate the... 2016-05-19 not-yet-due
Reported results 2013-002244-86 Effect of reparixin on long-term outcomes after pancreatic islet transplantation in type 1 diabetes mellitus patients. A non-interventional, monocentre study to extend up to 3 years the follow-up of p... 2015-06-23 due-trials
Reported results 2013-004271-12 An open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry Eye Eine offene Studie zur Evaluierung der Sich... 2015-01-30 due-trials
Reported results 2014-003968-20 A phase 2, multicentre, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes 2019-05-15 due-trials
Reported results 2014-004796-23 A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer... 2020-03-23 due-trials
Reported results 2016-002172-27 A 8 weeks, Phase II, single-centre, randomized, double-masked, vehicle-controlled, parallel group study with 4 weeks of follow-up to evaluate preliminary efficacy and safety of recombinant human Nerve... 2017-09-04 due-trials
Completed, but no date, and reported results Terminated 2019-002114-38 Randomized, single dose, placebo-controlled, double-blind, parallel group study to evaluate the onset of pain response after administration of ketoprofen lysine salt 40 mg, in male and female subjects... bad-data
Completed, but no date, and reported results Terminated 2020-001645-40 Adaptive phase 2/3, randomized, controlled multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with COVID-19 pneumonia Studio adattativo di fase 2/3,... bad-data
Other 2020-001926-71 A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the effect and safety of 400 mg twice a day oral ladarixin in patients with recent onset type 1 diabetes and a low ... not-yet-due
Listed as ongoing, but also has a completion date 2020-002966-15 A phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of 400 mg twice a day oral ladarixin in patients with new-onset type 1 diabetes and preserv... 2023-10-11 bad-data
Completed, report not yet due Terminated 2020-003296-18 Effect of oral ladarixin 400 mg twice a day on insulin sensitivity. A phase 2, randomized, double-blind, placebo-controlled explorative study in obese patients with pre-diabetes eligible to bariatric ... 2023-04-21 not-yet-due
Ongoing, reported early 2020-003936-25 Multicenter, adaptive, randomized, placebo-controlled, double blind, parallel-group Phase 2/3 trial, to study efficacy and safety of two doses of raloxifene in adult paucisymptomatic COVID-19 patients... not-yet-due
Completed, but no date, and reported results 2020-005919-51 A phase 3, double-blind, randomized, placebo-controlled, multicenter study on the efficacy and safety of Reparixin in the treatment of hospitalized patients with severe COVID-19 pneumonia. Studio m... bad-data
Reported results Terminated 2021-000382-32 A multicenter, randomized, double-blind, placebo-controlled phase 2 study to assess the efficacy and safety of oral reparixin in cancer related fatigue in patients with locally advanced or metastatic ... 2022-09-09 due-trials
Ongoing 2021-001629-38 A phase 2, multicenter, randomized, double blind, active controlled, parallel group study assessing the analgesic effect and safety of two doses of DFL24412 in patients with chronic low back pain comp... not-yet-due
Completed, but no date, and reported results Terminated 2021-002476-39 Prospective study to evaluate the effects of Raloxifene therapy on SARS-CoV-2 immunity after COVID-19 vaccination Prospective study to evaluate the effects of Raloxifene therapy on SARS-CoV-2 immun... bad-data
Reported results 2021-003346-21 A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution versus vehicle, in patients with sever... 2022-12-16 due-trials
Ongoing 2021-003749-39 A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with seve... not-yet-due
Ongoing 2021-006951-32 Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19 and other community-acquired pneumonia. A multinatio... not-yet-due
Completed, report not yet due Terminated 2022-000743-68 A phase II randomized, placebo-controlled, double-blinded, 2-parallel arm, clinical trial evaluating Ladarixin 400 mg twice a day as adjunctive therapy to improve glycemic control in overweight insuli... 2023-09-18 not-yet-due
Ongoing 2022-001612-25 Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with Acu... not-yet-due